Mezigdomide and Elranatamab for Relapsed and/or Refractory Multiple Myeloma

The goal of this clinical trial is to find out how well a combination of two medicines (mezigdomide and elranatamab) works in treating patients with refractory/relapsed multiple myeloma.

Trial Details

NCT ID
NCT06645678
Phase
PHASE1 / PHASE2
Sponsor
YOUNGIL KOH
Status
RECRUITING
Cancer Type
Relapsed/Refractory Multiple Myeloma
Interventions
  • Elranatamab
  • Mezigdomide
  • Dexamethasone
Locations (sample)
  • Singapore, Singapore|1.28967,103.85007
  • Singapore, Singapore|1.28967,103.85007
  • Hwasun, South Korea|35.06125,126.98746
  • Seoul, South Korea|37.566,126.9784
  • Seoul, South Korea|37.566,126.9784

Key Eligibility Criteria

  • Subjects must satisfy the following criteria to be enrolled in the study:
  • Subject is ≥ 19 years of age at the time of signing the informed consent form (ICF).
  • ② Subject must understand and voluntarily sign an ICF prior to any study-related assessments/procedures being conducted.
  • Subject is willing and able to adhere to the study visit schedule and other protocol requirements.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Relapsed/Refractory Multiple Myeloma Trials on Trialify →